A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life.
Judge’s ruling clears way for Aurion Biotech’s IPO, investor Alcon to appeal
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS